EUVIMEDEUVIMED entdecken
Crossref

Foxiangsan Modulates Dopaminergic and Motilin Pathways to Improve Gastrointestinal Motility in Diabetic Gastroparesis

Jukai Huang, Shu Zhang, Shuli Cheng, Xiaohui Yang

Neuroendocrinology · 05.03.2026 · 116 (4) · 200-218

DOI: 10.1159/000551403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuroendocrinology, online erschienen am 05.03.2026. Verfasst von Jukai Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Beijing University of Chinese Medicine, Dongzhimen Hospital, Beijing, China. Hauptthemen laut MEDLINE: Gastroparesis, Dopamine, Motilin, Gastrointestinal Motility. Die Arbeit nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Diabetic gastroparesis (DGP) is a severe diabetic complication with limited therapeutic options. This study investigates the effects of Foxiangsan on DGP and elucidates its molecular mechanisms.

Methods

A rat model of DGP was established and divided into 5 groups: model (MG), western medicine (WMG, domperidone), and 3 Foxiangsan dose groups (LDG, MDG, HDG). Serum dopamine (DA) and motilin levels, along with striatal DA receptor D2 (DRD2) expression, were measured. Network pharmacology identified bioactive compounds and targets, and pathway enrichment and molecular docking were used to evaluate mechanistic interactions.

Results

Foxiangsan significantly improved gastrointestinal motility, increased motilin levels, reduced DA levels, and enhanced DRD2 expression in the striatum. Network pharmacology identified DRD2, AKT1, and MAPK3 as key targets, while molecular docking confirmed strong binding affinities of bioactive compounds such as β-sitosterol and baicalein with DRD2. The therapeutic effects of Foxiangsan involve modulation of the cAMP, serotonin, and DA pathways.

Conclusion

Foxiangsan exerts multicomponent, multi-target, and multi-pathway actions in DGP by modulating neuroendocrine function, suggesting its potential as a novel therapeutic approach. Further investigations are needed to confirm its clinical efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GastroparesisDopamineMotilinGastrointestinal MotilityDiabetes ComplicationsAnimalsRatsMaleReceptors, Dopamine D2Rats, Sprague-DawleySignal TransductionMolecular Docking SimulationDrugs, Chinese HerbalDiabetes Mellitus, Experimental

Stichwörter der Autor:innen

Diabetic gastroparesisDopamine receptor D2FoxiangsanGastrointestinal motilityMolecular dockingNetwork pharmacology

Substanzen

Receptors, Dopamine D2DopamineMotilinDrugs, Chinese Herbal

Autor:innen und Institutionen

  • Department of Endocrinology, Beijing University of Chinese Medicine, Dongzhimen Hospital, Beijing, China.
  • Department of Neurology, Beijing University of Chinese Medicine, Fangshan Hospital, Beijing, China.
  • Department of Intensive Care Unit, Beijing University of Chinese Medicine, Dongzhimen Hospital, Beijing, China.
  • Department of Endocrinology, Beijing University of Chinese Medicine, Dongzhimen Hospital, Beijing, China, yxh0616@bucm.edu.cn.

Zitieren

APA

Huang, J., Zhang, S., Cheng, S., & Yang, X. (2026). Foxiangsan Modulates Dopaminergic and Motilin Pathways to Improve Gastrointestinal Motility in Diabetic Gastroparesis. Neuroendocrinology, 116(4), 200-218. https://doi.org/10.1159/000551403

Vancouver

Huang J, Zhang S, Cheng S, Yang X. Foxiangsan Modulates Dopaminergic and Motilin Pathways to Improve Gastrointestinal Motility in Diabetic Gastroparesis. Neuroendocrinology. 2026;116(4):200-218. doi:10.1159/000551403

BibTeX
@article{Huang2026,
  author = {Huang, Jukai and Zhang, Shu and Cheng, Shuli and Yang, Xiaohui},
  title = {Foxiangsan Modulates Dopaminergic and Motilin Pathways to Improve Gastrointestinal Motility in Diabetic Gastroparesis},
  journal = {Neuroendocrinology},
  year = {2026},
  volume = {116},
  number = {4},
  pages = {200--218},
  doi = {10.1159/000551403}
}
Kostenlos starten →